Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Indivior Pharmaceuticals (INDV) Debt to Equity (2021 - 2026)

Indivior Pharmaceuticals has reported Debt to Equity over the past 6 years, most recently at -$3.38 for Q1 2026.

  • For Q1 2026, Debt to Equity fell 192.36% year-over-year to -$3.38; the TTM value through Mar 2026 reached -$3.38, down 192.36%, while the annual FY2025 figure was -$3.26, 229.42% down from the prior year.
  • Debt to Equity for Q1 2026 was -$3.38 at Indivior Pharmaceuticals, down from -$3.26 in the prior quarter.
  • Over five years, Debt to Equity peaked at -$0.99 in Q4 2024 and troughed at -$16.0 in Q4 2022.
  • A 5-year average of -$3.61 and a median of -$1.43 in 2025 define the central range for Debt to Equity.
  • Biggest five-year swings in Debt to Equity: crashed 900.0% in 2022 and later soared 91.85% in 2023.
  • Year by year, Debt to Equity stood at -$16.0 in 2022, then soared by 91.85% to -$1.3 in 2023, then increased by 24.24% to -$0.99 in 2024, then crashed by 229.42% to -$3.26 in 2025, then fell by 3.68% to -$3.38 in 2026.
  • Business Quant data shows Debt to Equity for INDV at -$3.38 in Q1 2026, -$3.26 in Q4 2025, and -$1.56 in Q3 2025.